# A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

> **NCT03255694** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Dwarfism

## Interventions

- **DRUG:** PEG-somatropin

## Key facts

- **NCT ID:** NCT03255694
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-12
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255694, "A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03255694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*